Table 3.

Efficacy of second-generation tyrosine kinase inhibitors in phase 2 frontline studies

Nilotinib 400 mg twice daily (GIMEMA; n = 73)Nilotinib 400 mg twice daily (MDACC; n = 67)a,bDasatinib 100 mg once daily or 50 mg twice daily (MDACC; n = 62)b
MMR (%)
 3 months524224
 6 months667563
 12 months858171
CCyR (%)
 3 months789082
 6 months969694
 12 months969798
CMR (%)
 24 months12206
 36 months70NANA
Progression, n110

Abbreviations: CCyR, complete cytogenetic response; GIMEMA, Gruppo Italiano Malattie Ematologiche dell'Adulto; MDACC, M.D. Anderson Cancer Center; MMR, major molecular response; CMR, complete molecular response; NA, not available.

  • aIncludes only patients with chronic myeloid leukemia in chronic phase.

  • bOnly incudes evaluable patients.